Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a)
作者:P. Douglas Boatman、Thomas O. Schrader、Michelle Kasem、Benjamin R. Johnson、Philip J. Skinner、Jae-Kyu Jung、Jerry Xu、Martin C. Cherrier、Peter J. Webb、Graeme Semple、Carleton R. Sage、Jens Knudsen、Ruoping Chen、Andrew K. Taggart、Ester Carballo-Jane、Jeremy G. Richman
DOI:10.1016/j.bmcl.2010.03.062
日期:2010.5
Tricyclic pyrazole tetrazoles which are potent partial agonists of the high affinity niacin receptor, GPR109a, have been discovered and optimized. One of these compounds has proven to be effective at lowering free fatty acids in vitro and in vivo.
structure–odor relationships, we synthesized 13 analogs of compound 1 and evaluated their odors. As a result, it was found that the presence of two double-bonds and branched methyl group at the terminal position in the side chain was essential in order to have a citrus-like odor. Substitution of the side chain with appropriate length at the appropriate 4-position of the 2(5H)-furanone ring was also an important
FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
申请人:Boatman P. Douglas
公开号:US20090258892A1
公开(公告)日:2009-10-15
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor.
Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
Stereoselective [2+2]-Cycloadditions of chiral allenic ketones and alkenes: Applications towards the synthesis of benzocyclobutenes and endiandric acids
作者:Renyu Guo、Brittany P. Witherspoon、M. Kevin Brown
DOI:10.1016/j.tet.2022.132932
日期:2022.9
found utility in many contexts. Prior work has demonstrated an enantioselective isomerization/stereoselective [2 + 2] as a means to access bicyclo [4.2.0]octanes. Herein, the utility of this method is demonstrated towards the synthesis of benzocyclobutenes and a key intermediate towards the endiandric acids.